Interv Akut Kardiol. 2024;23(2-3):136-138 | DOI: 10.36290/kar.2024.015

CASTLE-HTx

Štěpán Havránek
II. interní klinika - klinika kardiologie a angiologie I. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice v Praze

The CASTLE HTx trial showed a significant reduction in the primary composite endpoint in patients with advanced heart failure with reduced ejection fraction and atrial fibrillation who were treated with catheter ablation in addition to optimal medical treatment of heart failure. Catheter ablation was compared with optimal medical treatment alone. The primary endpoint was a composite of death from any cause, implantation of a left ventricular assist device, and urgent heart transplantation.

Keywords: srdeční selhání se sníženou ejekční frakcí levé komory, terminální srdeční selhání, fibrilace síní, katetrizační ablace.

Received: July 31, 2024; Revised: July 31, 2024; Accepted: August 19, 2024; Published: December 12, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havránek Š. CASTLE-HTx. Interv Akut Kardiol. 2024;23(2-3):136-138. doi: 10.36290/kar.2024.015.
Download citation
PDF will be unlocked 12.12.2025

References

  1. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-520. Go to original source... Go to PubMed...
  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. Go to original source... Go to PubMed...
  3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. Go to original source... Go to PubMed...
  4. Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4). Go to original source... Go to PubMed...
  5. Marrouche NF, Kheirkhahan M, Brachmann J. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;379(5):492. Go to original source... Go to PubMed...
  6. Sohns C, Fox H, Marrouche NF, et al. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023;389(15):1380-9. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.